Table 2.
Overview of Baseline Characteristics of the Patient Population–CRC Cohort by Exposure to Travel Vaccines/Anti-Malarial Drugs
| Covariates | Unexposed |
Exposed |
||
|---|---|---|---|---|
| N | % | N | % | |
| Cohort size | 73,466 | 99.6 | 295 | 0.4 |
| Follow-up years (mean) | 7.9 | - | 3.7 | - |
| All-cause mortality | 34,028 | 46.3 | 36 | 12.2 |
| CRC-related mortality | 25,224 | 34.3 | 27 | 9.2 |
| Age at CRC diagnosis | ||||
| <50 y | 3900 | 5.3 | 49 | 16.6 |
| 50–59 y | 7236 | 9.8 | 69 | 23.4 |
| 60–69 y | 18,068 | 24.6 | 133 | 45.1 |
| ≥70 y | 44,262 | 60.2 | 44 | 15 |
| Sex | ||||
| Men | 38,581 | 52.5 | 155 | 52.5 |
| Women | 34,885 | 47.5 | 140 | 47.5 |
| Family income | ||||
| First quartile | 18,473 | 25.1 | 26 | 8.8 |
| Second quartile | 18,440 | 25.1 | 33 | 11.2 |
| Third quartile | 18,339 | 25 | 79 | 26.8 |
| Fourth quartile | 17,928 | 24.4 | 157 | 53.2 |
| Missing | 286 | 0.4 | 0 | 0 |
| Stage of disease at diagnosis (tnm) | ||||
| Stage I | 10,362 | 14.1 | 54 | 18.3 |
| Stage II | 18,203 | 24.8 | 76 | 25.8 |
| Stage III | 19,572 | 26.6 | 94 | 31.9 |
| Stage IV | 14,419 | 19.6 | 16 | 5.4 |
| Not assessed | 10,910 | 14.9 | 55 | 18.6 |